- Company supports BioFlorida and statewide life sciences industry growth -

BOCA RATON, Fla.--(BUSINESS WIRE)--Dec. 12, 2016-- TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women’s healthcare company headquartered in Boca Raton, announced the company’s participation in the 2016 BioFlorida Conference to be held in Jacksonville from December 11-13. Two TherapeuticsMD company executives, Chief Executive Officer Robert Finizio and Chief Product Officer Julia Amadio, will serve as industry expert guest speakers at the conference on the featured topics of Innovation and Women’s Health, respectively.

“The BioFlorida conference is an important opportunity to bring together members of the local life sciences industry, share best practices and learn from our respective experiences,” said TherapeuticsMD CEO Robert G. Finizio. “TherapeuticsMD is a strong supporter of the regional life sciences presence in South Florida as we pursue our mission to bring innovative healthcare solutions to women at all stages of their lives.”

TherapeuticsMD is a biopharmaceutical company currently developing a pipeline of hormone therapy products for post-menopausal women and marketing a suite of prescription prenatal vitamins throughout the United States. The company has over 175 employees, approximately 100 of whom work in the company’s Boca Raton office.

TherapeuticsMD is a sponsor of the 2016 BioFlorida Conference and an active member of BioFlorida, the statewide association representing the life sciences industry.

About BioFlorida

BioFlorida is the voice of Florida’s life sciences industry, representing nearly 6,000 establishments and research organizations in the biotechnology, pharmaceuticals, medical technology and bioagriculture sectors that collectively employ nearly 83,000 Floridians. The annual conference is BioFlorida’s largest and most comprehensive event of the year featuring an informative program showcasing science, business and public policy issues. More information is available on BioFlorida's website: www.bioflorida.com.

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is an innovative healthcare company focused on developing and commercializing products exclusively for women. With its SYMBODA™ technology, TherapeuticsMD is developing hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The company’s clinical development pipeline includes two phase 3 products. The company also manufactures and distributes branded and generic prescription prenatal vitamins as well as over-the-counter vitamins under the vitaMedMD^® and BocaGreenMD^® brands. More information is available at the following websites: www.therapeuticsmd.com, www.vitamedmd.com and www.bocagreenmd.com.

Forward-Looking Statements

This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the company’s ability to maintain or increase sales of its products; the company’s ability to develop and commercialize its hormone therapy drug candidates and obtain additional financing necessary therefor; whether the company will be able to prepare a new drug application for its TX-001HR product candidate and, if prepared, whether the FDA will accept and approve the application; whether the FDA will approve the company’s new drug application for its TX-004HR product candidate and whether any such approval will occur by the PDUFA date; the length, cost and uncertain results of the company’s clinical trials; the potential of adverse side effects or other safety risks that could preclude the approval of the company’s hormone therapy drug candidates; the company’s reliance on third parties to conduct its clinical trials, research and development and manufacturing; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company’s common stock and the concentration of power in its stock ownership. PDF copies of the company’s historical press releases and financial tables can be viewed and downloaded at its website: www.therapeuticsmd.com/pressreleases.aspx.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161212005329/en/

Source: TherapeuticsMD, Inc.

Investor:
TherapeuticsMD, Inc.
David DeLucia, 561-961-1900
Director, Investor Relations
David.DeLucia@TherapeuticsMD.com
or
Media:
SparkBioComm
Ami Knoefler, 650-739-9952
Ami@SparkBioComm.com